Baird analyst Catherine Ramsey Schulte downgraded Bio-Techne (TECH) to Neutral from Outperform with a price target of $68, down from $88. The firm has concerns around the future of National Institutes of Health funding, particularly after surveying academic researchers last week. Given these uncertainties and sentiment overhang, it downgrades the shares. While the stock has pulled back significantly since the Trump inauguration, Baird has “trouble seeing what gets sentiment working again absent some sort of resolution,” the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne’s Strong Growth Prospects and Strategic Positioning Drive Buy Rating
- Bio-Techne price target raised to $90 from $88 at Scotiabank
- Bio-Techne’s Strong Growth Prospects and Buy Rating Amidst Robust Q2 Results and Expanding Market Presence
- Bio-Techne price target raised to $88 from $86 at Baird
- Bio-Techne price target raised to $90 from $80 at KeyBanc